Changes in purchasing patterns after glucagon-like peptide-1 receptor agonist (GLP-1RA) initiation were seen across most nutrient ...
Key market opportunities for GLP-1 analogues include growth in the oral administration segment, expanding presence in Asia-Pacific and emerging markets, and strategic partnerships. Regulatory ...
US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that may mimic GLP-1 drugs for years after ...
News Medical on MSN
New trial tests strategies to protect heart health during prostate cancer therapy
City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by ...
Grocery industry organisation IGD (the Institute of Grocery Distribution) has launched an insight programme focused on GLP-1 ...
News-Medical.Net on MSN
Why exercise is essential for restoring fitness after GLP-1-based weight loss
By Vijay Kumar Malesu New trial evidence shows that without structured exercise, weight loss medications may leave physical ...
Hosted on MSN
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a long-acting amylin analogue developed by Danish biotech Gubra. Announced on 3 ...
Researchers conducted a cohort study to assess the effect of incretin receptor agonist therapy on continuous positive airway pressure use in T2D, obesity, and OSA.
A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...
Sun Pharma has received approval from the Drugs Controller General of India to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results